open access

Vol 14, No 6 (2018)
Review paper
Published online: 2019-03-15
Get Citation

Liposarcoma — spectrum of disease

Hanna Koseła-Paterczyk, Michał Wągrodzki
DOI: 10.5603/OCP.2018.0047
·
Oncol Clin Pract 2018;14(6):341-347.

open access

Vol 14, No 6 (2018)
REVIEW ARTICLES
Published online: 2019-03-15

Abstract

Liposarcomas are the most common soft tissue sarcomas in adults. Diagnosis and treatment of liposarcoma should always be planned and conducted in centres experienced in the treatment of these heterogeneous malignancies with different prognosis and sensitivity to the treatment used. In the following paper, we present a summary of current knowledge about liposarcomas considering the differences between subtypes and new directions in treatment.

Abstract

Liposarcomas are the most common soft tissue sarcomas in adults. Diagnosis and treatment of liposarcoma should always be planned and conducted in centres experienced in the treatment of these heterogeneous malignancies with different prognosis and sensitivity to the treatment used. In the following paper, we present a summary of current knowledge about liposarcomas considering the differences between subtypes and new directions in treatment.
Get Citation

Keywords

soft tissue sarcoma; liposarcoma; multimodality therapy

About this article
Title

Liposarcoma — spectrum of disease

Journal

Oncology in Clinical Practice

Issue

Vol 14, No 6 (2018)

Article type

Review paper

Pages

341-347

Published online

2019-03-15

DOI

10.5603/OCP.2018.0047

Bibliographic record

Oncol Clin Pract 2018;14(6):341-347.

Keywords

soft tissue sarcoma
liposarcoma
multimodality therapy

Authors

Hanna Koseła-Paterczyk
Michał Wągrodzki

References (48)
  1. Hoang NT, Acevedo LA, Mann MJ, et al. A review of soft-tissue sarcomas: translation of biological advances into treatment measures. Cancer Manag Res. 2018; 10: 1089–1114.
  2. Fletcher CDM. The evolving classification of soft tissue tumours - an update based on the new 2013 WHO classification. Histopathology. 2014; 64(1): 2–11.
  3. Dalal KM, Kattan MW, Antonescu CR, et al. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006; 244(3): 381–391.
  4. Lucas DR, Nascimento AG, Sanjay BK, et al. Well-differentiated liposarcoma. The Mayo Clinic experience with 58 cases. Am J Clin Pathol. 1994; 102(5): 677–683.
  5. London J, Kim EE, Wallace S, et al. MR imaging of liposarcomas: correlation of MR features and histology. J Comput Assist Tomogr. 1989; 13(5): 832–835.
  6. Creytens D, van Gorp J, Savola S, et al. Atypical spindle cell lipoma: a clinicopathologic, immunohistochemical, and molecular study emphasizing its relationship to classical spindle cell lipoma. Virchows Arch. 2014; 465(1): 97–108.
  7. McCarthy AJ, Chetty R. Tumours composed of fat are no longer a simple diagnosis: an overview of fatty tumours with a spindle cell component. J Clin Pathol. 2018; 71(6): 483–492.
  8. Sato D, Suga H, Takushima A. Liposarcoma Preoperatively Diagnosed as Lipoma: 10-Year Experience at a Single Institution. Dermatol Surg. 2018; 44(8): 1065–1069.
  9. Weaver J, Goldblum JR, Turner S, et al. Detection of MDM2 gene amplification or protein expression distinguishes sclerosing mesenteritis and retroperitoneal fibrosis from inflammatory well-differentiated liposarcoma. Mod Pathol. 2009; 22(1): 66–70.
  10. Mariño-Enriquez A, Nascimento AF, Ligon AH, et al. Atypical Spindle Cell Lipomatous Tumor: Clinicopathologic Characterization of 232 Cases Demonstrating a Morphologic Spectrum. Am J Surg Pathol. 2017; 41(2): 234–244.
  11. Mentzel T, Palmedo G, Kuhnen C. Well-differentiated spindle cell liposarcoma ('atypical spindle cell lipomatous tumor') does not belong to the spectrum of atypical lipomatous tumor but has a close relationship to spindle cell lipoma: clinicopathologic, immunohistochemical, and molecular analysis of six cases. Mod Pathol. 2010; 23(5): 729–736.
  12. Patel RB, Li T, Liao Z, et al. Recent translational research into targeted therapy for liposarcoma. Stem Cell Investig. 2017; 4: 21.
  13. Arrigoni G, Doglioni C. Atypical lipomatous tumor: molecular characterization. Curr Opin Oncol. 2004; 16(4): 355–358.
  14. Thway K, Flora R, Shah C, et al. Diagnostic utility of p16, CDK4, and MDM2 as an immunohistochemical panel in distinguishing well-differentiated and dedifferentiated liposarcomas from other adipocytic tumors. Am J Surg Pathol. 2012; 36(3): 462–469.
  15. Evans HL, Soule EH, Winkelmann RK. Atypical lipoma, atypical intramuscular lipoma, and well differentiated retroperitoneal liposarcoma: a reappraisal of 30 cases formerly classified as well differentiated liposarcoma. Cancer. 1979; 43(2): 574–584.
  16. Kindblom LG, Angervall L, Fassina AS. Atypical lipoma. Acta Pathol Microbiol Immunol Scand A. 1982; 90(1): 27–36.
  17. Evans HL. Liposarcoma: a study of 55 cases with a reassessment of its classification. Am J Surg Pathol. 1979; 3(6): 507–523.
  18. Saeed-Chesterman D, Thway K. Homologous Lipoblastic Differentiation in Dedifferentiated Liposarcoma. Int J Surg Pathol. 2016; 24(3): 237–239.
  19. Evans HL. Atypical lipomatous tumor, its variants, and its combined forms: a study of 61 cases, with a minimum follow-up of 10 years. Am J Surg Pathol. 2007; 31(1): 1–14.
  20. Mussi C, Collini P, Miceli R, et al. The prognostic impact of dedifferentiation in retroperitoneal liposarcoma: a series of surgically treated patients at a single institution. Cancer. 2008; 113(7): 1657–1665.
  21. Gronchi A, Collini P, Miceli R, et al. Myogenic differentiation and histologic grading are major prognostic determinants in retroperitoneal liposarcoma. Am J Surg Pathol. 2015; 39(3): 383–393.
  22. Dei Tos AP. Liposarcomas: diagnostic pitfalls and new insights. Histopathology. 2014; 64(1): 38–52.
  23. Creytens D, Van Gorp J, Speel EJ, et al. Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis. Anticancer Res. 2015; 35(4): 1835–1842.
  24. Orvieto E, Furlanetto A, Laurino L, et al. Myxoid and round cell liposarcoma: a spectrum of myxoid adipocytic neoplasia. Semin Diagn Pathol. 2001; 18(4): 267–273.
  25. Estourgie SH, Nielsen GP, Ott MJ. Metastatic patterns of extremity myxoid liposarcoma and their outcome. J Surg Oncol. 2002; 80(2): 89–93.
  26. Kilpatrick SE, Doyon J, Choong PF, et al. The clinicopathologic spectrum of myxoid and round cell liposarcoma. A study of 95 cases. Cancer. 1996; 77(8): 1450–1458, doi: 10.1002/(SICI)1097-0142(19960415)77:8<1450::AID-CNCR5>3.0.CO;2-G.
  27. Smith TA, Easley KA, Goldblum JR. Myxoid/round cell liposarcoma of the extremities. A clinicopathologic study of 29 cases with particular attention to extent of round cell liposarcoma. Am J Surg Pathol. 1996; 20(2): 171–180.
  28. Wang L, Ren W, Zhou X, et al. Pleomorphic liposarcoma: a clinicopathological, immunohistochemical and molecular cytogenetic study of 32 additional cases. Pathol Int. 2013; 63(11): 523–531.
  29. Ghadimi MP, Liu P, Peng T, et al. Pleomorphic liposarcoma: clinical observations and molecular variables. Cancer. 2011; 117(23): 5359–5369.
  30. Miettinen M, Enzinger FM. Epithelioid variant of pleomorphic liposarcoma: a study of 12 cases of a distinctive variant of high-grade liposarcoma. Mod Pathol. 1999; 12(7): 722–728.
  31. Huang HY, Antonescu CR. Epithelioid variant of pleomorphic liposarcoma: a comparative immunohistochemical and ultrastructural analysis of six cases with emphasis on overlapping features with epithelial malignancies. Ultrastruct Pathol. 2002; 26(5): 299–308.
  32. Val-Bernal JF, González-Vela MC, Cuevas J. Primary purely intradermal pleomorphic liposarcoma. J Cutan Pathol. 2003; 30(8): 516–520.
  33. Wang L, Luo R, Xiong Z, et al. Pleomorphic liposarcoma: An analysis of 6 case reports and literature review. Medicine (Baltimore). 2018; 97(8): e9986.
  34. Mariño-Enríquez A, Hornick JL, Dal Cin P, et al. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration. Cancer Cytopathol. 2014; 122(2): 128–137.
  35. Crago AM, Dickson MA. Liposarcoma: Multimodality Management and Future Targeted Therapies. Surg Oncol Clin N Am. 2016; 25(4): 761–773.
  36. Rutkowski P, Ługowska I. (red.). Mięsaki tkanek miękkich u dorosłych. Onkol Prakt Klin Edu 2017;3(5):203-225.
  37. Crago AM, Singer S. Clinical and molecular approaches to well differentiated and dedifferentiated liposarcoma. Curr Opin Oncol. 2011; 23(4): 373–378.
  38. Gronchi A, Lo Vullo S, Fiore M, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol. 2009; 27(1): 24–30.
  39. Gronchi A, Ferrari S, Quagliuolo V, et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017; 18(6): 812–822.
  40. Casali Pg, Abecassis N, Aro Ht, Et Al. Soft Tissue And Visceral Sarcomas: Esmo-Euracan Clinical Practice Guidelines For Diagnosis, Treatment And Follow-Up. Ann Oncol. 2018;29(Supplement_4):Iv268-Iv269.
  41. Chung PWM, Deheshi BM, Ferguson PC, et al. Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas. Cancer. 2009; 115(14): 3254–3261.
  42. Pawlik T, Pisters P, Mikula L, et al. Long-Term Results of Two Prospective Trials of Preoperative External Beam Radiotherapy for Localized Intermediate- or High-Grade Retroperitoneal Soft Tissue Sarcoma. Annals of Surgical Oncology. 2006; 13(4): 508–517.
  43. Jones RL, Fisher C, Al-Muderis O, et al. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005; 41(18): 2853–2860.
  44. Patel SR, Burgess MA, Plager C, et al. Myxoid liposarcoma. Experience with chemotherapy. Cancer. 1994; 74(4): 1265–1269.
  45. Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009; 27(25): 4188–4196.
  46. Jones RL, Demetri GD, Schuetze SM, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016; 34(8): 786–793.
  47. Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol. 2009; 20(8): 1439–1444.
  48. Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007; 8(7): 595–602.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl